Australia’s vivoPharm To Buy RMIT Testing Firm For 20% Stock Share
This article was originally published in PharmAsia News
Executive Summary
Australia’s vivoPharm plans to buy RMIT University’s RMIT Drug Discovery Technologies, the buyer to move its headquarters from Adelaide to Melbourne to be closer to the nation’s biotechnology center.